1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025

Report Details
Clinical Trials – Discover Commercial Potentials of Outsourced Drug Testing, Benefiting Your Authority
What does the future hold for pharmaceutical clinical research providers? Visiongain’s new study gives you multilevel revenue forecasts from 2015 to 2025. It explains trends, opportunities and selling prospects for that drug development and testing.

Our report predicts sales at overall world market, submarket and national level. There you find the most promising and lucrative parts of clinical trial outsourcing, helping your research and analysis. That way stay ahead, saving time and hassle, also benefiting your influence.

Clinical research organisations (CROs) and drug companies using them will benefit from expansion of that industry and market. Those technologies and outsourced services hold rising importance in pharmaceutical R&D. See why and how, finding the gains possible.

Read on, then, to explore those contracting services for benefiting medicine. Find what influences that market and see predicted revenue.

Forecasts and other analyses to help you stay ahead in knowledge
Why struggle to find information or miss data you need on clinical outsourcing and off-shoring? Instead reduce worry there, helping your searches, proposals and presentations.

So in our work discover where the money lies, and best places for business expansion. In that study you explore revenue forecasting to 2025, results and other statistics, growth rates, leading companies and market shares.

You also assess qualitative analysis (SWOT and STEP), news, business progress, outlooks and developmental needs – pharma R&D trends and demands. You find expected gains.

There you get 78 tables, 65 charts and interviews with three companies. The clinical testing market will increase its revenues from 2015 to 2025, achieving strong sales expansion. Our survey’s purpose is to explain those needs, opportunities and potentials.

That way you hear what’s happening, helping you stay ahead. And the following sections explain how our new investigation benefits your work.

Predictions for the world market and submarkets – what’s possible?
Along with revenue prediction for the overall world market, you see individual forecasts to 2025 for nine submarkets:
- Early phase services
- Late phase services
- Other related services (grouped).

You also get individual forecasts for contract clinical services at world level by therapeutic area:
- Cancer (oncology)
- Cardiovascular diseases
- CNS disorders
- Metabolic conditions
- Infective diseases
- Other treatment testing needs (grouped prediction).

There gain advantages by understanding trends, needs, opportunities and challenges. Our investigation shows what will stimulate and restrain CROs, helping you stay ahead in knowledge. That way, benefit your business and reputation for commercial insight.

Our work also divides its overall world sales forecast into geographical markets.

Clinical trial outsourcing – what prospects for research in leading regions and countries?
Demands worldwide from drug developers influence service providers from 2015, especially extending clinical research in developing countries. Many opportunities exist for pharmaceutical companies and contract research providers. See outlooks for clinical testing.

Our new study gives individual forecasts to 2025 for 12 national markets and a regional group, predicting overall revenues:
- United States (US)
- Japan
- Germany, France, UK, Italy and Spain (EU5 countries)
- Central and Eastern Europe (CEE, grouped forecast of that region)
- Brazil, Russia, India and China (BRIC nations) and South Korea.

There discover progress and commercial outlooks. You assess the industry’s future – hear about developments and find their significance. Our work explains, ex

Table Of Contents

Pharma Clinical Trial Services: World Industry and Market Prospects 2015-2025
Table of Contents
1. Report Overview
1.1 Overview of the World Market for Pharma Clinical Trial Services
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. An Introduction to Clinical Trial Outsourcing
2.1 A Brief History of Clinical Trials
2.2 Clinical Trial Design and Execution
2.2.1 Phases of Clinical Trials
2.2.1.1 Phase I Trials: First-In-Human Studies
2.2.1.2 Phase II Trials: Proof-Of-Concept
2.2.1.3 Phase III Trials: Preparing for Approval Applications
2.2.1.4 Post-Marketing Studies
2.2.2 Key Elements of Clinical Trials
2.2.3 Common Trial Designs
2.2.3.1 Improving Clinical Trial Models through Adaptive Trial Designs
2.3 Clinical Trial Outsourcing
2.3.1 Challenges Exist in Conducting Clinical Trials
2.3.2 Benefits of Outsourcing
3. Pharma Clinical Trial Services: World Market 2015-2025
3.1 The World Pharma Clinical Trial Services Market in 2013 and 2014
3.1.1 The Impact of the Economy on the Clinical Trial Services Market, 2008-2014
3.1.2 CRO Revenue by Trial Phase 2014
3.1.3 Big Pharma Companies Are the Leading Clients for CROs
3.2 The Pharma Clinical Trial Services Market 2015-2025
3.2.1 What Will Drive Growth in Clinical Trial Outsourcing 2015-2025?
3.2.2 The Pharma Clinical Trial Services Market: Overall Revenue Forecast 2015-2025
3.2.3 Which Market Sector Will Account for the Most Revenue from 2015-2025?
3.3 Early Phase Clinical Trial Services 2015-2025
3.3.1 Rising Demand for Early Phase Services throughout the Decade
3.3.2 Biotech Outsourcing to Drive Early Phase Growth
3.4 Late Phase Clinical Trial Services 2015-2025
3.4.1 Late Phase Clinical Trial Services: The Largest Market Sector 2015-2025
3.4.2 Focus on Late-Stage Pipeline Candidates Early in the Decade
4. Pharma Clinical Trial Services: Leading Developed National Markets 2015-2025
4.1 Leading National Markets for Pharma Clinical Trial Services 2014
4.2 Pharma Clinical Trial Services: Leading National Market Forecasts 2015-2025
4.3 North America as a Destination for Clinical Trials
4.3.1 The US: The Largest National Market for Clinical Trial Services 2015-2025
4.3.1.1 Regulatory Developments to Improve Clinical Trials in the US
4.3.2 The US: Clinical Trial Service Revenue Forecast 2015-2025
4.4 The Outlook for Clinical Trial Services in the EU5 2015-2025
4.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
4.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025
4.4.3 Germany Is the Largest Market for Clinical Trial Services in Western Europe
4.4.4 The UK
4.4.4.1 Overcoming Challenges in UK Clinical Trials
4.4.4.2 UK Clinical Trial Services Market Forecast 2015-2025
4.4.5 France: Market Forecast 2015-2025
4.4.6 Italy: Market Forecast 2015-2025
4.4.7 Spain: Market Forecast 2015-2025
4.5 Japan Is Being Challenged by Neighbouring Emerging Markets
4.5.1 Regulatory Policies Driving and Restraining Growth in Japan
4.5.2 Growth for Clinical Trial Services in Japan 2015-2025
5. Pharma Clinical Trial Services: Leading Emerging National Markets 2015-2025
5.1 Leading Emerging Markets for Clinical Trial Services 2014
5.1.1 Benefits of Conducting Clinical Trials in Emerging Markets
5.1.2 Challenges of Conducting Clinical Trials in Emerging Markets
5.2 Strong Growth Forecast for Emerging Clinical Trial Service Markets 2015-2025
5.3 Clinical Trials in Asia Pacific: An Emerging Market Perspective
5.3.1 China Will be the Largest Emerging Market for Clinical Trials Services in 2025
5.3.1.1 CRO Investments and Partnerships in China
5.3.1.2 Chinese Clinical Trial Services Market Forecast 2015-2025
5.3.1.3 China Offers Many Advantages in Clinical Trials
5.3.1.4 New Guidelines by the China Food and Drug Administration (CFDA)
5.3.2 India as a Hub for Clinical Trials
5.3.2.1 Increasingly Strict Regulatory Procedures in India
5.3.2.2 Indian Clinical Trial Services Market Forecast 2015-2025
5.3.3 South Korea
5.3.3.1 Improving the Appeal of South Korea
5.3.3.2 Promoting Local Drug Development in South Korea
5.3.3.3 Growth in the South Korean Clinical Trials Services Market 2015-2025
5.4 Clinical Trial Outsourcing in Central and Eastern Europe (CEE)
5.4.1 Russia
5.4.1.1 Changing Clinical Trial Demands 2010-2015
5.4.1.2 Russian Clinical Trial Services Market Forecast 2015-2025
5.4.2 CEE: Clinical Trial Services Market Forecast 2015-2025
5.5 Latin America: Proximity to the US as a Growth Driver
5.5.1 Brazil: The Largest Market for Clinical Trials in Latin America 2015-2025
5.5.1.1 Brazilian Clinical Trial Services Market Forecast 2015-2025
6. Leading Disease Market Sectors for Clinical Trial Services 2015-2025
6.1 Rise in Clinical Trials, 2000-2015
6.2 The Pharma Clinical Trial Services Market by Therapeutic Area 2014-2015
6.3 The Pharma Clinical Trial Services Market: Revenue Forecasts by Therapeutic Area 2015-2025
6.3.1 Imaging for CNS and Cardiovascular Clinical Trials
6.4 Cancer Clinical Trials: Key Trends and Submarket Forecast 2015-2025
6.4.1 Biomarkers and Companion Diagnostic Development
6.4.2 Optimising Patient Recruitment and Retention
6.4.3 Many Factors Complicate Cancer Clinical Trials
6.4.4 Will Cancer Be the Largest Submarket for Clinical Trial Services 2015-2025?
6.5 Cardiovascular Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
6.5.1 Strong Growth in the Cardiovascular Disease Clinical Trial Services Submarket 2015-2025
6.6 CNS Clinical Trials: Key Trends and Submarket Forecast 2015-2025
6.6.1 Late-Stage Failures in Alzheimer's Pipeline, 2009-2014
6.6.2 Concerns with Placebo Response Rates in CNS Clinical Trials
6.6.2.1 Cogtest Clinical: Data Capture and Cognitive Assessment
6.6.3 Effective Use of Adaptive Trial Designs
6.6.4 CNS Clinical Trials: Submarket Forecast 2015-2025
6.7 Infectious Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
6.7.1 Challenges in the Use of Non-Inferiority Trials
6.7.2 Considerations for Antibacterial Drug Clinical Trials
6.7.3 Vaccine Clinical Trials and Emerging Markets
6.7.4 Infectious Disease Clinical Trial Services Submarket Forecast 2015-2025
6.8 Metabolic Disease Clinical Trials: Key Trends and Submarket Forecast 2015-2025
6.8.1 Assessing Cardiovascular Risks in Diabetes
6.8.2 Metabolic Disease Clinical Trial Services Submarket Forecast 2015-2025
6.9 Therapeutic Expertise Provides an Opportunity for Specialisation
6.9.1 CROs Offering Imaging Services
7. Pharma Clinical Trial Services Market: Industry Trends 2015-2025
7.1 Pharma Clinical Trial Services Market: Strengths and Weaknesses 2014
7.2 Pharma Clinical Trial Services Market: Opportunities and Threats 2015-2025
7.2.1 Opportunities for CROs in Biosimilar Development
7.3 Pharma Clinical Trial Services Market: STEP Analysis 2015-2025
7.4 Social Factors Affecting Clinical Trials 2015-2025
7.4.1 Drug Developers Must Deal with Ethical Considerations to Clinical Trials
7.4.2 Patient Recruitment: The Leading Cause of Trial Delays
7.4.3 Investing to Maintain Patient Enrolment
7.4.3.1 Social Media as a Tool for Engaging Patients in Trials
7.5 Improving Technology for More-Efficient Trials
7.5.1 eClinical Trial Tools
7.5.1.1 Electronic Health Records for Faster Patient Recruitment
7.5.2 Cloud Computing as a Tool for Multicentre Trials
7.5.3 Electronic Data Capture
7.6 Economic Considerations for Clinical Trial Outsourcing
7.6.1 Pharma is Adjusting its RandD Strategies
7.6.2 CROs are Attractive for Private Investors
7.7 Political and Regulatory Developments Affecting Clinical Trials
7.7.1 Drug Safety and Clinical Trials Post-Approval
7.7.2 Cutting Red Tape and Other Regulatory Developments
7.8 Future Growth Strategies for CROs
7.8.1 Strategic Partnering for Long Term Revenue Growth
7.8.1.1 Sharing Risk Between Pharma and CROs
7.8.2 What Strategies Are Used for Selecting a CRO?
7.8.2.1 Small Pharmaceutical Companies and CROs
7.8.3 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players
7.8.4 CROs Can Specialise to Grow
7.8.4.1 Orphan Diseases Are an Opportunity for Specialisation
7.9 The Future of Clinical Trials and CROs
7.9.1 New Trial Designs
7.9.1.1 Optimising Clinical Trials for Efficient Drug Development
7.9.2 Clinical Trial Globalisation
7.9.2.1 Consequences of Increased Outsourcing to Emerging Markets
7.9.3 Clinical Trials Have Become Increasingly Complex
7.10 Biomarkers Are Useful Tools for Accelerating Drug Development
8. Leading CROs in the Clinical Trials Services Industry in 2015
8.1 The Pharma Clinical Trial Services Market by Company 2014
8.2 Quintiles: The Largest Player in the Pharma Clinical Trial Services Market
8.2.1 Embracing Technology for New Service Offerings
8.2.2 How Quintiles Remains a Leader in the Clinical Trials Market
8.2.2.1 An Increase in Emerging Biotech Customers in 2014
8.2.2.2 Expanding in Developed and Emerging Markets
8.2.3 Will Quintiles Remain the Market Leader to 2025?
8.3 Covance Acquired by Laboratory Corporation of America (LabCorp)
8.3.1 Covance Drug Development
8.3.2 Covance Reorganises its Early Phase Sites
8.3.3 Strong Late Phase Revenue Growth 2010-2014
8.3.4 How Will Covance Drug Development Extend its Services Beyond 2014?
8.4 Pharmaceutical Product Development (PPD)
8.4.1 PPD: Another Global CRO to be Taken Private
8.4.2 Investing in Technology for Growth
8.4.3 PPD: Outlook 2015-2025
8.5 Parexel International
8.5.1 Parexel is Targeting Growth in Asia
8.5.2 Strong Growth for Clinical Trial Services 2010-2014
8.5.3 New Areas of Specialisation for Parexel
8.6 ICON
8.6.1 Multiple Acquisitions Have Increased ICON's Service Range
8.6.1.1 Expanding Operations in China
8.6.2 ICON: Recent Financial Performance and Outlook 2015-2025
8.7 INC Research
8.7.1 From Mid-Sized to Large CRO: INC Acquires Kendle
8.7.2 INC Adds New Technological Capabilities
8.8 inVentiv Health
8.8.1 Four Acquisitions Move inVentiv Closer to the Big Players
8.8.2 Clinical Trial Service Revenue Growth 2011 and Beyond
8.9 PRA Health Sciences
8.9.1 New Site Openings in Emerging Markets 2011-2014
8.9.2 Future Directions for PRA Health Sciences
8.10 CMIC Holdings: Japan's Largest CRO
8.10.1 Increasing Asian Regional Reach
8.10.2 CMIC Recent and Future Performance Analysis: An Asian Specialist
8.11 Chiltern International
8.11.1 Expanding into New Emerging Markets with Expansion in Israel, Taiwan and Singapore
8.11.2 Chiltern International: Opportunities for Growth 2015-2025
8.12 There Are Many Other CROs in the Market in 2015
8.12.1 Charles River Laboratories Is an Expert in Pre-Clinical Services
8.12.2 Clinipace Worldwide Is a Digital CRO
8.12.2.1 Rapidly Expanding Through Acquisitions
8.12.2.2 Clinipace Offers Many Technology Solutions
8.12.3 Theorem Clinical Research
8.12.3.1 An Established Presence in China
8.12.4 WuXi PharmaTech
8.12.4.1 WuXi is New to the Clinical Trial Services Market
8.13 Leading Company Analysis
8.13.1 Emerging Market Entry and Expansion
8.13.2 How Are Global CROs Expanding Their Service Offerings and Utilising Technology?
8.13.3 How Are Leading Players Seeking to Differentiate Themselves?
8.13.4 Medium-Sized Players Growing Larger Through Multiple Acquisitions
8.13.5 Large CROs and Strategic Partnerships with Big Pharma
9. Research Interviews from Our Survey
9.1 Interview with Mark Egerton, CEO of Quotient Clinical
9.1.1 Quotient Clinical's Translational Pharmaceutics Platform
9.1.2 Quotient Clinical in the Global Market
9.1.3 Challenges for the Pharma Clinical Trial Services Market
9.1.4 Pharma Clinical Trial Services Market Size, 2015-2025
9.2 Interview with Dean Knuth, Executive Director Clinical Sciences of MPI Research
9.2.1 On Changes in the Outsourcing Market
9.2.2 MPI Research Acquires Jasper Clinical
9.2.3 Future Outlook for MPI Research
9.2.4 Drivers and Restraints in Early Phase Clinical Trial Services
9.2.5 Technological Advances in Clinical Trials Services
9.2.6 On the Early Phase Development Market Size
9.3 Interview with Ewan Campbell, Director of The Clinical Trial Company
9.3.1 Clinical Trial Services Offered at TCTC
9.3.2 Drivers and Restraints for Outsourcing Late-Phase Development
9.3.3 Potential Impact of the EU Clinical Trial Regulation on the Clinical Trial Services
9.3.4 Trends Affecting the Clinical Trial Services Market, 2015-2025
10. Conclusions from Our Research and Analysis
10.1 The State of the Clinical Trial Services Market in 2014
10.1.1 A Market Dominated by the Developed Countries
10.2 Strong Growth for the Overall Market 2015-2025
10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
10.3.1 The Role of Technology in the Future of Clinical Trial Services
10.3.2 How Can CROs Specialise to Remain Competitive?

List of Tables
Table 1.1 Pharma Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
Table 2.1 Founding Members of the ICH
Table 2.2 Types of Adaptive Trial Design
Table 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
Table 3.2 Pharma Clinical Trial Services Market by Sector, 2014
Table 3.3 CRO Clinical Trial Services Revenue by Customer Type, 2014
Table 3.4 Pharma Clinical Trial Services Market: Overall Market and Revenue Forecasts ($bn) by Sector, 2014-2025
Table 3.5 Clinical Trial Services Submarket Shares, 2014-2025
Table 3.6 Early Phase Clinical Trial Services Submarket Forecast ($bn), 2015-2025
Table 3.7 Late Phase Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 4.1 World Pharma Clinical Trial Services Market by Region, 2014
Table 4.2 Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) by Country, 2014-2025
Table 4.3 Pharma Clinical Trial Services: Market Shares by Country, 2014-2025
Table 4.4 US Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.5 EU5 Clinical Trial Services Market by Country, 2014
Table 4.6 Number of CRO Offices in the EU5 by Country, 2015
Table 4.7 EU5 Clinical Trial Services Market: Revenue Forecasts ($bn) by Country, 2014-2025
Table 4.8 German Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.9 UK Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.10 French Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.11 Italian Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.12 Spanish Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 4.13 Japanese Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.1 Leading Emerging Markets for Pharma Clinical Trial Services, 2014
Table 5.2 Population Statistics in BRIC Nations, May 2015
Table 5.3 English Proficiency in Emerging Markets, 2014
Table 5.4 Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) in Emerging Markets, 2014-2025
Table 5.5 Chinese Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.6 Indian Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.7 South Korean Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.8 Russian Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.9 CEE Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 5.10 Brazilian Clinical Trial Services Market Forecast ($bn), 2014-2025
Table 6.1 Number of Registered Studies, 2000-2015
Table 6.2 Global Clinical Trials (Phase I-IV) by Therapeutic Area, 2015
Table 6.3 Leading Therapeutic Areas for Clinical Trial Services, 2014
Table 6.4 Clinical Pipelines for Leading Therapeutic Areas, Numbers of Studies, 2014
Table 6.5 Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) for Leading Therapeutic Areas, 2014-2025
Table 6.6 Selected CROs Specialising in Biomarker Services, 2015
Table 6.7 Cancer Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
Table 6.8 Cancer Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 6.9 Cardiovascular Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 6.10 Cardiovascular Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
Table 6.11 Late-Stage Pipeline Failures in Alzheimer's Disease, 2009-2014
Table 6.12 Approved Therapies for Alzheimer's Disease, 1996-2014
Table 6.13 CNS Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
Table 6.14 CNS Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 6.15 Hepatitis C: Global Prevalence by Region, 2014
Table 6.16 Infectious Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 6.17 Infectious Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
Table 6.18 Metabolic Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Table 6.19 Metabolic Disease Clinical Trial Services Submarket: Drivers and Restraints, 2014-2025
Table 6.20 Selected Imaging Specialist CROs, 2015
Table 7.1 Pharma Clinical Trial Services Market: Strengths and Weaknesses, 2014
Table 7.2 Pharma Clinical Trial Services Market: Opportunities and Threats, 2015-2025
Table 7.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
Table 7.4 Pharma Clinical Trial Services Market: STEP Analysis, 2015-2025
Table 7.5 Selected Online Communities to Aid Patient Recruitment and Trial Involvement, 2015
Table 7.6 Selected CROs Investing in Technology, 2011-2014
Table 7.7 Selected Sources of Biomarkers and Relevant Research Technology, 2015
Table 8.1 Revenues ($bn) of Selected CROs, 2014
Table 8.2 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 8.3 Covance Drug Development: Service Revenue ($bn) by Segment, 2010-2014
Table 8.4 PPD: Service Revenue ($bn) and Revenue Share (%) by Sector, 2010
Table 8.5 Parexel International: Service Revenue by Sector ($bn) and CAGR (%), 2010- 2014 (Year Ending 30 June)
Table 8.6 Parexel International: Service Revenue ($bn), AGR (%), and CAGR (%), 2012- 2014 (Year Ending 31 December)
Table 8.7 Parexel International: Service Revenue ($bn) and Revenue Share (%) by Region, 2013 and 2014
Table 8.8 ICON: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
Table 8.9 ICON: Net Revenue ($bn) and CAGR (%) by Region, 2012-2014
Table 8.10 Kendle: Service Revenue ($bn) and AGR (%) by Sector, 2009-2010
Table 8.11 INC Research: Service Revenue ($bn), AGR (%), and CAGR (%), 2011-2014
Table 8.12 inVentiv Health: Service Revenue ($bn) and AGR (%) by Sector, Q2 2010 and Q2 2011
Table 8.13 PRA Health Sciences: Service Revenue ($bn), AGR (%), and CAGR (%), 2010-2014
Table 8.14 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014
Table 8.15 Chiltern International: Therapeutic Experience
Table 8.16 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
Table 8.17 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
Table 8.18 Selected Strategic Partnerships Signed, 2011-2014
Table 10.1 Pharma Clinical Trial Services Market by Sector, 2014, 2019 and 2025

List of Figures
Figure 2.1 Brief History of Clinical Trials
Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
Figure 3.2 Pharma Clinical Trial Services Market by Sector, 2014
Figure 3.3 CRO Clinical Trial Services Revenue by Customer Type, 2014
Figure 3.4 Clinical Trial Services Market: Drivers and Restraints, 2015-2025
Figure 3.5 Pharma Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 3.6 Pharma Clinical Trial Services Market by Sector, 2019
Figure 3.7 Pharma Clinical Trial Services Market by Sector, 2025
Figure 3.8 Early Phase Clinical Trial Services Submarket Forecast ($bn), 2015-2025
Figure 3.9 Early Phase Trial Services Submarket: Drivers and Restraints, 2015-2025
Figure 3.10 Late Phase Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 3.11 Late Phase Trial Services Submarket: Drivers and Restraints, 2015-2025
Figure 4.1 World Pharma Clinical Trial Services Market by Region, 2014
Figure 4.2 World Pharma Clinical Trial Services Market by Region, 2019
Figure 4.3 World Pharma Clinical Trial Services Market by Region, 2025
Figure 4.4 US Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.5 EU5 Clinical Trial Services Market by Country, 2014
Figure 4.6 Number of CRO Offices in the EU5 by Country, 2015
Figure 4.7 EU5 Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.8 German Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.9 UK Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.10 French Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.11 Italian Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.12 Spanish Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 4.13 Japanese Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.1 Leading Emerging Markets for Pharma Clinical Trial Services, 2014
Figure 5.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
Figure 5.3 Relative Competence in English in Emerging Markets, 2012
Figure 5.4 Pharma Clinical Trial Services: Emerging Market Forecasts ($bn), 2014-2025
Figure 5.5 Chinese Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.6 Indian Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.7 South Korean Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.8 Russian Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.9 CEE Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 5.10 Brazilian Clinical Trial Services Market Forecast ($bn), 2014-2025
Figure 6.1 Number of Registered Studies, 2000-2015
Figure 6.2 Global Clinical Trials by Therapeutic Area, 2014
Figure 6.3 Leading Therapeutic Areas for Clinical Trial Services, 2014
Figure 6.4 Leading Therapeutic Areas for Clinical Trial Services, 2014
Figure 6.5 Pharma Clinical Trial Services Market: Revenue Forecasts ($bn) for Leading Therapeutic Areas, 2014, 2019 and 2025
Figure 6.6 Cancer Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 6.7 Cardiovascular Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 6.8 CNS Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 6.9 Hepatitis C: Global Prevalence by Region, 2014
Figure 6.10 Infectious Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 6.11 Metabolic Disease Clinical Trial Services Submarket Forecast ($bn), 2014-2025
Figure 7.1 The 3+3 Staging Trial Design
Figure 8.1 Revenues ($bn) of Selected CROs, 2014
Figure 8.2 Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014
Figure 8.3 Covance Drug Development: Service Revenue ($bn) by Segment, 2010-2014
Figure 8.4 PPD: Service Revenue Share (%) by Sector, 2010
Figure 8.5 Parexel International: Service Revenue ($bn) by Sector, 2010-2014 (Year Ending 30 June)
Figure 8.6 Parexel International: Service Revenue ($bn) and AGR (%), 2012-2014 (Year Ending 31 December)
Figure 8.7 Parexel International: Service Revenue Share (%) by Region, 2014*
Figure 8.8 ICON: Service Revenue ($bn) and AGR (%), 2010-2014
Figure 8.9 ICON: Net Revenue Share (%) by Region, 2014
Figure 8.10 Kendle: Service Revenue Share (%) by Sector, 2010
Figure 8.11 INC Research: Gross and Net Service Revenue ($bn) and AGR (%), 2011-2014
Figure 8.12 inVentiv Health: Service Revenue ($bn) by Sector, Q2 2010 and Q2 2011
Figure 8.13 PRA Health Sciences: Service Revenue ($bn) and AGR (%) 2010-2014
Figure 8.14 CMIC: CRO Service Revenue ($bn), 2011-2014
Figure 8.15 Chiltern International's Clinical Trials: Therapeutic Experience
Figure 8.16 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014
Figure 8.17 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
Figure 10.1 Pharma Clinical Trial Services Market by Sector, 2014, 2019 and 2025

Companies Listed
3C Alliance
Actavis
Adamas Pharmaceuticals
Adheris (an InVentiv Health company)
Administration of Science, Technology and Training (ASST) [Vietnam]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agenzia Italiana del Farmaco (AIFA) [Italy]
Agilent Technologies
Agility Clinical
AKESOgen
Akos
Allscripts
Amgen
Aptiv Solutions (now part of ICON plc)
Aptuit
ASAN Medical Center
Assent Consulting
Associação Brasileira de CROs (Abracro)
Association for the Accreditation of Human Research Protection Programs (AAHRPP)
Association of Clinical Trial Organisations (ACTO) [Russia]
Astellas Pharma
Avista Capital Partners
Baxter International
Bayer
BeijingWits Medical Consulting (part of ICON)
Ben's Friends
Berry Consultants
BioBay
BioClinica
BioDuro (part of PPD)
BioDuro Biologics
Biogen Idec
Biomedical Systems
BioTrak
Bioxydyn
BML
Boehringer Ingelheim
Bridgepoint Development Capital
Bristol-Myers Squibb
Caprion
Catalent
Catalina Health (part of InVentiv Health)
Celerion
Center for Biologics Evaluation and Research (CBER) [US]
CenterWatch
Central Drugs Standard Control Organization (CDSCO) [India]
Center for Drug Evaluation (CDE)
Charles River Laboratories
China Food and Drug Administration (CFDA)
Chinese Ministry of Commerce
ClinForce
Clinical Trial Support
Clinigene International
Clinipace Worldwide
ClinStar
CMIC Holdings
CMIC (Beijing) Co
CNS Healthcare
CNS Vital Signs
Cogtest (part of The Cognition Group)
Corex Pharmaceutical
Council for International Organizations of Medical Sciences (CIOMS)
CRI Lifetree (part of PRA Health Sciences)
Cromos Pharma
CROMSOURCE
Cross Country Healthcare Inc
Czura Thornton
Dako (part of Agilent Technologies)
Department of Health [UK]
Department of Health and Human Services [US]
Drug Controller General of India (DCGI)
Duke Clinical Research Institute
EF Education First
Eisai
Ekam Imaging
Eli Lilly
EPS Corporation (now EPS Holdings, Inc.)
EPS Holdings, Inc.
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Parliament
Firecrest Clinical (part of ICON)
Forest Pharmaceuticals
Food and Drug Administration (US FDA)
Frontage Laboratories
GCP ClinPlus
GE Healthcare
Genstar Capital
Global CNS Research
Global Research Services (GRS)
G?ówny Urz?d Statystyczny (Polish Central Statistical Office)
GSK
Harlan Laboratories (part of Huntingdon Life Sciences)
Hellman and Friedman
Hisun Pharmaceuticals
Hospital Italiano de Buenos Aires
Huntingdon Life Sciences
i3 Research (part of inVentiv Health)
ICON
ImageIQ
ImmuneHealth
INC Research
Infociencia (part of RPS)
Innovative Medicines Initiative (IMI)
Inspire
Institute for Medical Research Management and Biometrics (IMEREM, part of RPS)
Integrium
International Cancer Genome Consortium
International Conference of Harmonisation (ICH)
inVentiv Health
JandJ
Janssen Pharmaceuticals (a subsidiary of JandJ)
Japan Pharmaceutical Manufacturers Association (JPMA)
Jasper Clinical Research and Development Inc.
Java Clinical
JCL Bioassay Corporation (part of CMIC Holdings)
Julphar
Kendle (part of INC Research)
Kester Capital
Kforce
Kforce Clinical Research (KCR, part of inVentiv Health)
Kinship Technologies (part of PRA Health Sciences)
KKR
Korea Drug Development Fund (KDDF)
Korea Food and Drug Administration (KFDA)
Korea National Enterprise for Clinical Trials (KoNECT)
Kun Tuo (part of Quintiles)
L'Agence Nationale de Securite du Medicament (L'ANSM) [France]
Laboratory Corporation of America (LabCorp)
Les Entreprises du Medicament (LEEM)
LSK Global
MAB Discovery
Malaysian Biotechnology Corporation
Massachusetts General Hospital
Maximax Pharmaceutical Research
MDS Pharma Services (part of INC Research)
MedAvante
Medaxial
Medelis
Medicines and Healthcare products Regulatory Agency (MHRA) [UK]
Medidata Solutions
MediMedia Pharma Solutions (now part of ICON plc)
Medipal Holdings
Medivation
MEK Consulting (part of INC Research)
Merck and Co.
Merck BioVentures
Merck KGaA
Metabolon
MetricStream
Ministry of Health, Labor and Welfare (MHLW, Japan)
Ministry of Public Health [Russia]
Mitsubishi Gas Chemical Company, Inc.
Molecular NeuroImaging
MorphoSys
MPI Research
MRM Proteomics
Myriad Genetics
Mytrus
National Cancer Institute (NCI) [US]
National Institute for Health and Care Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
National Taiwan University Hospital (NTUH)
Nautic Partners
NeuroImage
NextGen Sciences
Nexus Oncology, an Ockham Company (formerly Nexus Oncology)
NHS Research Scotland (NRS)
Novartis
Novotech
Ockham
OCT
Omnicare
Oncobiologics
Ontario Teachers' Pension Plan
Oxford Cancer Biomarkers
Oxford Gene Technology (OGT)
Oxford Outcomes (part of ICON)
Pacific Biomarkers
Paragon Biomedical (part of Clinipace Worldwide)
Paramax International (part of RPS)
Parexel International
PatientsLikeMe
Perceptive Informatics (part of Parexel)
PFC Pharma Focus (part of Clinipace Worldwide)
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
PharmaNet Development Group (part of inVentiv Health)
Pharmaron
PPD
PRA International
Prana Biotechnology
PriceSpective (part of ICON)
Prodia Clinical Laboratory
Proteome Sciences
ProTrials Research
PSR Orphan Experts
Psychmed (part of The Cognition Group)
QED Clinical Services
Quintiles
Quotient Clinical
RCT Logic
Regulus Pharmaceutical Consulting (part of Clinipace Worldwide)
ReSearch Pharmaceutical Services (RPS, part of PRA International)
Roche
Rules Based Medicine (now Myriad RBM, part of Myriad Genetics)
Samsung
SAS
Seoul National University Hospital Clinical Trial Center
Shanghai Clinical Research Center
ShangPharma
Shire
State Food and Drug Administration (SFDA) [China] (now CFDA)
Syngene International
Sugi Medical Co (part of CMIC)
Taijitu Biologics
Targos Molecular Pathology
Tessella
The Carlyle Group
The Clinical Trial Company
The Cognition Group
Theorem Clinical Research
Theradex Systems
Therapeutic Goods Administration (TGA) [Australia]
Therapharm Recherches (part of RPS)
Thomas H. Lee Partners
Tigermed Consulting
Timaq Medical Imaging (part of ICON)
Trident Clinical Research (part of INC Research)
UCB
University of Manchester
Veeda Clinical Research
Veeva Systems
Vigiun (part of Chiltern International)
VirtualScopics
Warburg Pincus
West Coast Clinical Trials (WCCT)
World Health Organization (WHO)
World Heart Foundation
Worldwide Clinical Research
WuXi AppTec
WuXi PharmaTech
Yungjin Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.